Key result
Vancouver 3M TAVI pathway is linked to ~89% lower 30-day mortality and safe early discharge.
Why the study?
Data on the safety of early hospital discharge after TAVI among patients residing in Northern Ontario, including remote and medically underserved areas, were lacking.
Does early discharge using the Vancouver 3M clinical pathway reduce resource utilization without compromising safety in patients undergoing TAVI in Northern Ontario?
Cohort (n=291)
No
Does early discharge using the Vancouver 3M clinical pathway reduce resource utilization without compromising safety in patients undergoing TAVI in Northern Ontario?
Implementation of the Vancouver 3M clinical pathway for TAVI in a rural/remote setting safely reduced hospital length of stay and resource utilization without increasing 30-day mortality.
Answers are grounded in this paper and cite their sources.
Supports early TAVI discharge in rural cohorts; extends 3M pathway data but remains hypothesis-generating pending prospective trials.
Background: Early hospital ( < 48 hours) discharge following transcatheter aortic valve implantation (TAVI) is an increasingly adopted practice; however, data on the safety of such an approach among patients residing in North Ontario, including remote and medically underserved areas, are lacking. Methods: This retrospective study included patients who underwent TAVI in Sudbury, Ontario. The safety of early discharge after implementation of the Vancouver 3M (multidisciplinary, multimodality, but minimalist) clinical pathway was assessed. The primary endpoint was 30-day mortality. Resource utilization before vs after 3M clinical pathway implementation was also compared. Results: A total of 291 patients who underwent TAVI between 2012 and 2021 were included in the study. One in-hospital death (0.6%) occurred after the 3M clinical pathway implementation, with no mortality observed beyond hospital discharge. Eleven patients (6.7%) required rehospitalization within 30 days. The need for mechanical ventilation and surgical vascular cut-down declined from 100% and 97%, respectively, at baseline, to 6% and 2%. The number of patients receiving TAVI on a given procedural day increased from 2 to 3 patients. The median post-TAVI hospital length of stay decreased from 5 days (2-6 days) to 1 day (1-3 days) after 3M clinical pathway implementation. Conclusions: Following TAVI, early discharge of selected patients residing in Northern Ontario, including rural areas, using the Vancouver 3M clinical pathway was associated with favourable outcomes, short length of stay, and more-efficient resource utilization. These data can help improve healthcare efficiency and bridge variations in TAVI funding and accessibility in underserved locations.
No takes yet. Share an insight, caveat, or question.
Hanna et al. (2022) conducted a cohort in Severe aortic stenosis (n=291). Vancouver 3M TAVI clinical pathway vs. Pre-implementation standard care was evaluated on 30-day mortality. The Vancouver 3M clinical pathway for TAVI facilitated safe early discharge with a 30-day mortality rate of 0.6% compared to 5.6% before implementation, reducing median length of stay to 1 day.
Synapse has enriched 10 related papers. Consider them for comparative context: